Dhanireddy, K. K., Bruno, D. A., Zhang, X., Leopardi, F. V., Johnson, L. B., & Kirk, A. D. (2006). Alefacept (LFA3-Ig), portal venous donor specific transfusion (PVDST), and sirolimus prolong renal allograft survival in non-human primates. In Journal of the American College of Surgeons (Vol. 203, pp. S92–S92). Ovid Technologies (Wolters Kluwer Health). https://doi.org/10.1016/j.jamcollsurg.2006.05.240

Dhanireddy, Kiran K., David A. Bruno, Xiaojie Zhang, Frank V. Leopardi, Lynt B. Johnson, and Allan D. Kirk. “Alefacept (LFA3-Ig), portal venous donor specific transfusion (PVDST), and sirolimus prolong renal allograft survival in non-human primates.” In Journal of the American College of Surgeons, 203:S92–S92. Ovid Technologies (Wolters Kluwer Health), 2006. https://doi.org/10.1016/j.jamcollsurg.2006.05.240.

Dhanireddy KK, Bruno DA, Zhang X, Leopardi FV, Johnson LB, Kirk AD. Alefacept (LFA3-Ig), portal venous donor specific transfusion (PVDST), and sirolimus prolong renal allograft survival in non-human primates. In: Journal of the American College of Surgeons. Ovid Technologies (Wolters Kluwer Health); 2006. p. S92–S92.

Dhanireddy, Kiran K., et al. “Alefacept (LFA3-Ig), portal venous donor specific transfusion (PVDST), and sirolimus prolong renal allograft survival in non-human primates.” Journal of the American College of Surgeons, vol. 203, no. 3, Ovid Technologies (Wolters Kluwer Health), 2006, pp. S92–S92. Crossref, doi:10.1016/j.jamcollsurg.2006.05.240.

Dhanireddy KK, Bruno DA, Zhang X, Leopardi FV, Johnson LB, Kirk AD. Alefacept (LFA3-Ig), portal venous donor specific transfusion (PVDST), and sirolimus prolong renal allograft survival in non-human primates. Journal of the American College of Surgeons. Ovid Technologies (Wolters Kluwer Health); 2006. p. S92–S92.